UNSPSC 51294701: Dicarbine

This classification denotes an antioxidant and antiarrhythmic agent with the molecular formula C13H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y0EA50IJ3V, chemically known as 2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1h-pyrido(4,3-b)indole but generally known as dicarbine, which bears US NIH Compound Identifier 65684. European Medicines Agency schedules Dicarbine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07081MIG.

UNSPSC 51294701 Dicarbine is a Commodity code for pharmaceutical active ingredients and chemical compounds used in drug manufacturing and formulation. Recent state and local procurement activity under this code, however, shows limited direct purchasing of dicarbine itself; instead, issuers are buying naloxone, generic pharmaceuticals, and drug deactivation systems through competitive bidding and cooperative purchasing vehicles. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances such as MMCAP. Work solicited ranges from direct purchase of finished naloxone units and safe drug deactivation systems for community health programs to broad pharmaceutical supply agreements encompassing generic multi-source drugs and over-the-counter products distributed through authorized wholesalers.

Geographic activity centers on Florida and the upper Midwest, with Texas also entering the market through preliminary market research. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026, emphasizing quarterly deliveries and full vendor responsibility for shipping costs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, establishing multi-award contracts effective July 1, 2026 across participating states including Oregon. The Texas Health and Human Services Commission issued a preliminary Request for Information (HHS0017013) in April 2026 to explore vendor capabilities for direct-to-manufacturer prescription programs, signaling future formal procurement activity. Vendors pursuing opportunities under this code should expect compliance requirements including cGMP certification, DSCSA compliance, E-Verify authorization, and insurance mandates ranging from $2 million to $5 million per occurrence depending on the scope and issuer.